← SynDRA
TEPOTINIB
SynDRA canonical compound SYN0038135 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | MET |
|---|
| Mechanism of action | Hepatocyte growth factor receptor inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- Hepatocyte growth factor receptor inhibitor
- MET INHIBITOR
- IRAK4 INHIBITOR
- MET MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- SYK
- AAK1
- NEK7
- PFKP
- PEBP1
- PDXK
- PDGFRB
- PASK
- PAK6
- PAK4
- PAK2
- PAICS
- OPA1
- OLA1
- NUAK2
- NTRK1
- NLK
- PGRMC1
- PHKG2
- PIM1
- PRKACA
- PRKCA
- PRKAR2A
- PRKAG2
- PRKAG1
- PRKACG
- PRKACB
- PRKAA1
- PIP4K2A
- PLK4
- PLK1
- PKN2
- PKN1
- PKMYT1
- PIP4K2C
- NEK9
- NEK3
- PRKCD
- MAPK10
- MAPK8
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Antineoplastic Agents
- Kinase Inhibitor
- P-Glycoprotein Inhibitors
- Mesenchymal Epithelial Transition Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- TEPMETKO
- Tepmetko
- tepotinib hydrochloride
- tepmetko
- EMD-1214063
- MSC-2156119
- MSC-2156119J
- EMD1214063
- MSC2156119
- EMD 1214063
- UNII-1IJV77EI07
- Tepotinib (EMD 1214063)
- 1IJV77EI07
- C29H28N6O2
- Tepotinib [INN]
- msc2156119j
- tepotinibum
- RefChem:57995
- DTXCID0071623
- c-Met Inhibitor MSC2156119J
- Tepotinib [USAN]
- Tepotinib(EMD-1214063)
- 3E8
- MFCD18452823
- Tepotinib (Standard)
- Tepotinib (USAN/INN)
- Tepotinib [USAN:INN]
- TEPOTINIB [WHO-DD]
- MLS006010785
- GTPL8293
- SCHEMBL1296895
- SCHEMBL29379106
- EX-A394
- AHYMHWXQRWRBKT-UHFFFAOYSA-N
- GLXC-06048
- WHO 9934
- BDBM50065457
- HY-14721R
Reported adverse events
- Nausea
- Vomiting
- Abdominal pain
- Constipation
- Cough
- Fatigue
- Hepatotoxicity
- Infection
- Musculoskeletal pain
- Pleural effusion
- Pneumonia
- Pneumonitis
Look up TEPOTINIB in the interactive SynDRA portal →